Related references
Note: Only part of the references are listed.Recombinant human endostatin plus paclitaxel/nedaplatin for recurrent or metastatic advanced esophageal squamous cell carcinoma: a prospective, single-arm, open-label, phase II study
Zhi-Qiang Wang et al.
INVESTIGATIONAL NEW DRUGS (2021)
Docetaxel and nedaplatin twice a week with concurrent definitive radiotherapy in inoperable esophageal squamous cell carcinoma: A phase I trial (GASTO-1021)
Nai-Bin Chen et al.
RADIOTHERAPY AND ONCOLOGY (2021)
TERT promoter regulating melittin expression induces apoptosis and G0/G1 cell cycle arrest in esophageal carcinoma cells
Chao Zhou et al.
ONCOLOGY LETTERS (2021)
microRNA-10b confers cisplatin resistance by activating AKT/mTOR/P70S6K signaling via targeting PPARγ in esophageal cancer
Kai Wu et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2020)
Postoperative short-term outcomes of minimally invasive versus open esophagectomy for patients with esophageal cancer: An updated systematic review and meta-analysis
Naeem M. Akhtar et al.
THORACIC CANCER (2020)
The Drug-Resistance Mechanisms of Five Platinum-Based Antitumor Agents
Jiabei Zhou et al.
FRONTIERS IN PHARMACOLOGY (2020)
High vs. Low Radiation Dose of Concurrent Chemoradiotherapy for Esophageal Carcinoma With Modern Radiotherapy Techniques: A Meta-Analysis
Xin Sun et al.
FRONTIERS IN ONCOLOGY (2020)
Immune checkpoint inhibitors for esophageal squamous cell carcinoma: a narrative review
Wencheng Zhang et al.
ANNALS OF TRANSLATIONAL MEDICINE (2020)
Predictive value of EGF and uPAR for chemoradiotherapy response and survival in patients with esophageal squamous cell carcinoma
Xi Chen et al.
ANNALS OF TRANSLATIONAL MEDICINE (2020)
TRIP13 upregulation is correlated with poor prognosis and tumor progression in esophageal squamous cell carcinoma
Shouyin Di et al.
PATHOLOGY RESEARCH AND PRACTICE (2019)
Esophageal and Esophagogastric Junction Cancers, Version 2.2019
Jaffer A. Ajani et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2019)
Esophageal cancer practice guidelines 2017 edited by the Japan esophageal society: part 2
Yuko Kitagawa et al.
ESOPHAGUS (2019)
Thyroid hormone receptor interactor 13 (TRIP13) overexpression associated with tumor progression and poor prognosis in lung adenocarcinoma
Wei Li et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2018)
SLC52A3 expression is activated by NF-κB p65/Rel-B and serves as a prognostic biomarker in esophageal cancer
Lin Long et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2018)
Riboflavin Depletion Promotes Tumorigenesis in HEK293T and NIH3T3 Cells by Sustaining Cell Proliferation and Regulating Cell Cycle-Related Gene Transcription
Lin Long et al.
JOURNAL OF NUTRITION (2018)
Nedaplatin Plus Docetaxel Versus Cisplatin Plus Docetaxel as First-Line Chemotherapy for Advanced Squamous Cell Carcinoma of the Lung - A Multicenter, Open-label, Randomized, Phase III Trial
Shun Lu et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
The comings and goings of PARP-1 in response to DNA damage
John M. Pascal
DNA REPAIR (2018)
Mechanism for remodelling of the cell cycle checkpoint protein MAD2 by the ATPase TRIP13
Claudio Alfieri et al.
NATURE (2018)
Silencing TRIP13 inhibits cell growth and metastasis of hepatocellular carcinoma by activating of TGF-β1/smad3
Jianning Yao et al.
CANCER CELL INTERNATIONAL (2018)
DNA repair pathways and cisplatin resistance: an intimate relationship
Clarissa Ribeiro Reily Rocha et al.
CLINICS (2018)
Feasibility of definitive chemoradiation therapy with nedaplatin and 5-fluorouracil in elderly patients with esophageal squamous cell carcinoma: A retrospective study
Akinori Watanabe et al.
ADVANCES IN RADIATION ONCOLOGY (2018)
Efficacy and safety of cisplatin-based versus nedaplatin-based regimens for the treatment of metastatic/recurrent and advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis
Fei Zhang et al.
DISEASES OF THE ESOPHAGUS (2017)
The multifaceted roles of PARP1 in DNA repair and chromatin remodelling
Arnab Ray Chaudhuri et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2017)
TRIP13 impairs mitotic checkpoint surveillance and is associated with poor prognosis in multiple myeloma
Yi Tao et al.
ONCOTARGET (2017)
Loss of thyroid hormone receptor interactor 13 inhibits cell proliferation and survival in human chronic lymphocytic leukemia
Keshu Zhou et al.
ONCOTARGET (2017)
TRIP13-deficient tubular epithelial cells are susceptible to apoptosis following acute kidney injury
Jeffrey D. Pressly et al.
SCIENTIFIC REPORTS (2017)
The AAA plus ATPase TRIP13 remodels HORMA domains through N-terminal engagement and unfolding
Qiaozhen Ye et al.
EMBO JOURNAL (2017)
Platinum-based drugs: past, present and future
Shahana Dilruba et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2016)
Tumor profiling of gastric and esophageal carcinoma reveal different treatment options
John T. Miura et al.
CANCER BIOLOGY & THERAPY (2015)
Inhibition of Autophagy Potentiated the Antitumor Effect of Nedaplatin in Cisplatin-Resistant Nasopharyngeal Carcinoma Cells
Zhongyu Liu et al.
PLOS ONE (2015)
Expression of ERCC1, RRM1 and LRP in Non-small Cell Lung Cancers and their Influence on Chemotherapeutic Efficacy of Gemcitabine Concomitant with Nedaplatin
Zhen-Qin Qiu et al.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION (2014)
Identification of a novel lysyl oxidase-like 2 alternative splicing isoform, LOXL2 Δe13, in esophageal squamous cell carcinoma
Guo-Qing Lv et al.
BIOCHEMISTRY AND CELL BIOLOGY-BIOCHIMIE ET BIOLOGIE CELLULAIRE (2014)
Disassembly of mitotic checkpoint complexes by the joint action of the AAA-ATPase TRIP13 and p31comet
Esther Eytan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
TRIP13 promotes error-prone nonhomologous end joining and induces chemoresistance in head and neck cancer
Rajat Banerjee et al.
NATURE COMMUNICATIONS (2014)
Functional variants in TNFAIP8 associated with cervical cancer susceptibility and clinical outcomes
Ting-Yan Shi et al.
CARCINOGENESIS (2013)
Application of liposomal technologies for delivery of platinum analogs in oncology
Demin Liu et al.
INTERNATIONAL JOURNAL OF NANOMEDICINE (2013)
Treatments for esophageal cancer: a review
Hiroyuki Kato et al.
GENERAL THORACIC AND CARDIOVASCULAR SURGERY (2013)
Playing the End Game: DNA Double-Strand Break Repair Pathway Choice
J. Ross Chapman et al.
MOLECULAR CELL (2012)
Molecular mechanisms of cisplatin resistance
L. Galluzzi et al.
ONCOGENE (2012)
Tyrosine dephosphorylation of H2AX modulates apoptosis and survival decisions
Peter J. Cook et al.
NATURE (2009)
The gamma-H2A.X: Is it just a surrogate marker of double-strand breaks or much more?
Ismail Hassan Ismail et al.
ENVIRONMENTAL AND MOLECULAR MUTAGENESIS (2008)
Therapeutic strategies in oesophageal carcinoma: role of surgery and other modalities
Christophe Mariette et al.
LANCET ONCOLOGY (2007)
Caspase family proteases and apoptosis
TJ Fan et al.
ACTA BIOCHIMICA ET BIOPHYSICA SINICA (2005)
The DNA damage-induced decrease of Bcl-2 is secondary to the activation of apoptotic effector caspases
J Milosevic et al.
ONCOGENE (2003)
Particular aspects of platinum compounds used at present in cancer treatment
B Desoize et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2002)
Share Paper
